Results 21 to 30 of about 1,923,383 (256)

Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness

Cell Research, 2023
Tonic signaling of chimeric antigen receptor (CAR), i.e., the spontaneous CAR activation in the absence of tumor antigen stimulation, is considered to be a pivotal event controlling CAR-T efficacy.
Jian Chen, Shi-Zhen Qiu, Wen-Tao Li, Kun Wang, Yu Zhang, Han Yang, Baichuan Liu, Guang-Fei Li, Li Li, Min Chen, Jun-Jie Lan, Jia-Hua Niu, P. He, Lei Cheng, G. Fan, Xin Liu, Xianmin Song, Chen-Qi Xu, Haitao Wu, Hao-Peng Wang   +19 more
semanticscholar   +1 more source

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Frontiers in Immunology, 2018
Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for ...
Rohtesh S. Mehta, Katayoun Rezvani
doaj   +1 more source

Chimeric Antigen Receptor Therapy

New England Journal of Medicine, 2018
Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors.
C. June, M. Sadelain
semanticscholar   +1 more source

Deletion of the inhibitory co-receptor CTLA4 enhances and invigorates chimeric antigen receptor T cells

Immunity, 2023
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous success treating B-cell malignancies, however some patients fail to respond due to poor autologous T cell fitness.
Sangya Agarwal, M. A. Aznar, Andrew J. Rech, Charly R. Good, Shunichiro Kuramitsu, Tong Da, M. Gohil, Linhui Chen, S. Hong, Pranali Ravikumar, Austin K. Rennels, January Salas-McKee, Weimin Kong, M. Ruella, M. Davis, G. Plesa, J. Fraietta, David L. Porter, R. Young, C. June   +19 more
semanticscholar   +1 more source

Supplementary Data from Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors

, 2022
Supplementary Data from Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid ...
Xin Liu (15098717), Boning Zhang (5209397), Qian Luo (610818), John V. Napoleon (12093653), Philip S. Low (15098720), Suilan Zheng (2389246)   +5 more
core   +1 more source

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies

Transplant Infectious Disease, 2023
Chimeric antigen receptor (CAR)‐T‐cell therapies have revolutionized the management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and multiple myeloma but come at the price of unique toxicities, including cytokine release syndrome, immune ...
E. Kampouri, J. Little, Kai Rejeski, O. Manuel, Sarah P. Hammond, J. Hill   +5 more
semanticscholar   +1 more source

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Nature Medicine, 2018
Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL).
J. Fraietta, S. Lacey, Elena J. Orlando, Iulian Pruteanu-Malinici, M. Gohil, Stefan Lundh, Alina C. Boesteanu, Yan Wang, Roddy S. O'Connor, W. Hwang, E. Pequignot, David E. Ambrose, Changfeng Zhang, Nicholas Wilcox, Felipe Bedoya, C. Dorfmeier, Fang Chen, Li-Feng Tian, Harit Parakandi, M. Gupta, R. Young, F. B. Johnson, I. Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, M. Davis, Bruce L. Levine, N. Frey, Don L. Siegel, Alexander C. Huang, E. Wherry, H. Bitter, J. Brogdon, David L. Porter, Carl H. June, J. Melenhorst   +36 more
semanticscholar   +1 more source

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Nature Communications, 2023
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a highly enriched cell surface antigen expressed in prostate cancer. Here the authors describe the design of STEAP1 directed CART cells and show their antitumor activity in preclinical ...
V. Bhatia, Nikhil V. Kamat, T. Pariva, Li-Ting Wu, Annabelle Tsao, Koichi Sasaki, Huiyun Sun, Gerardo Javier, Sam Nutt, I. Coleman, Lauren Hitchcock, Ai-Lin Zhang, Dmytro Rudoy, R. Gulati, Radhika J. Patel, M. Roudier, L. True, Shivani Srivastava, C. Morrissey, Michael C. Haffner, Peter S. Nelson, S. Priceman, J. Ishihara, John K. Lee   +23 more
semanticscholar   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

New England Journal of Medicine, 2016
SUMMARY A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2).
Christine E. Brown, D. Alizadeh, R. Starr, L. Weng, Jamie R. Wagner, A. Naranjo, J. Ostberg, M. S. Blanchard, J. Kilpatrick, Jennifer Simpson, Anita Kurien, S. Priceman, Xiu-Li Wang, T. Harshbarger, M. D'Apuzzo, J. Ressler, M. Jensen, M. Barish, M. Chen, J. Portnow, S. Forman, B. Badie   +21 more
semanticscholar   +1 more source